Zusammenfassung
Diese Einschätzung wurde am 01.11.18 mit einem Endkurs von 13,53 € beendet. Die Einschätzung zu Merus BV enttäuschte mit einer Rendite von -16,67 %. stratec hat 50% Zuversicht bei dieser Einschätzung
Finanztrends
Rendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Merus BV | - | - | - | - |
| iShares Core DAX® | -0.874% | 5.325% | 6.865% | 65.211% |
| iShares Nasdaq 100 | -0.381% | 1.979% | 25.696% | 90.325% |
| iShares Nikkei 225® | -1.676% | 1.952% | 41.443% | 80.623% |
| iShares S&P 500 | -0.655% | 2.069% | 21.405% | 70.737% |
Kommentare von stratec zu dieser Einschätzung
In der Diskussion Merus BV diskutieren
Merus will yield meaningful clinical data in the near future.
A lucrative partnership was signed with Incyte last year for which they received $120 million upfront and a common share purchase of $80 million. Incyte in return received exclusive rights for up to 11 bispecific antibody research programs utilizing Merus' Biclonics technology, which included two preclinical immuno-oncology candidates.
The technology of Merus has the potential to be sufficiently differentiated from monoclonal antibodies due to improved tumor cell killing activity and lower toxicity.
(Laufzeit überschritten)